Standard

Injection drug use and hepatitis C virus infection in young adult injectors: using evidence to inform comprehensive prevention. / Page, Kimberly; Morris, Meghan D.; Hahn, Judith A. et al.

In: Clinical infectious diseases, Vol. 57, No. Suppl. 2, 2013, p. S32-S38.

Research output: Contribution to journalArticleAcademicpeer-review

Harvard

Page, K, Morris, MD, Hahn, JA, Maher, L & Prins, M 2013, 'Injection drug use and hepatitis C virus infection in young adult injectors: using evidence to inform comprehensive prevention', Clinical infectious diseases, vol. 57, no. Suppl. 2, pp. S32-S38. https://doi.org/10.1093/cid/cit300

APA

Vancouver

Author

Page, Kimberly ; Morris, Meghan D. ; Hahn, Judith A. et al. / Injection drug use and hepatitis C virus infection in young adult injectors: using evidence to inform comprehensive prevention. In: Clinical infectious diseases. 2013 ; Vol. 57, No. Suppl. 2. pp. S32-S38.

BibTeX

@article{ae212e32edc9438e85be4808f97e2cdc,
title = "Injection drug use and hepatitis C virus infection in young adult injectors: using evidence to inform comprehensive prevention",
abstract = "The hepatitis C virus (HCV) virus epidemic is ongoing in the United States and globally. Incidence rates remain high, especially in young adult injection drug users. New outbreaks of HCV in the United States among young adults, in predominantly suburban and rural areas, have emerged and may be fueling an increase in HCV. This paper discusses some key HCV prevention strategies that to date have not been widely researched or implemented, and wherein future HCV prevention efforts may be focused: (1) reducing sharing of drug preparation equipment; (2) HCV screening, and testing and counseling; (3) risk reduction within injecting relationships; (4) injection cessation and {"}breaks{"}; (5) scaled-up needle/syringe distribution, HCV treatment, and vaccines, according to suggestions from mathematical models; and (6) {"}combination prevention.{"} With ongoing and expanding transmission of HCV, there is little doubt that there is a need for implementing what is in the prevention {"}toolbox{"} as well as adding to it. Strong advocacy and resources are needed to overcome challenges to providing the multiple and comprehensive programs that could reduce HCV transmission and associated burden of disease worldwide in people who inject drugs",
author = "Kimberly Page and Morris, {Meghan D.} and Hahn, {Judith A.} and Lisa Maher and Maria Prins",
year = "2013",
doi = "10.1093/cid/cit300",
language = "English",
volume = "57",
pages = "S32--S38",
journal = "Clinical infectious diseases",
issn = "1058-4838",
publisher = "Oxford University Press",
number = "Suppl. 2",

}

RIS

TY - JOUR

T1 - Injection drug use and hepatitis C virus infection in young adult injectors: using evidence to inform comprehensive prevention

AU - Page, Kimberly

AU - Morris, Meghan D.

AU - Hahn, Judith A.

AU - Maher, Lisa

AU - Prins, Maria

PY - 2013

Y1 - 2013

N2 - The hepatitis C virus (HCV) virus epidemic is ongoing in the United States and globally. Incidence rates remain high, especially in young adult injection drug users. New outbreaks of HCV in the United States among young adults, in predominantly suburban and rural areas, have emerged and may be fueling an increase in HCV. This paper discusses some key HCV prevention strategies that to date have not been widely researched or implemented, and wherein future HCV prevention efforts may be focused: (1) reducing sharing of drug preparation equipment; (2) HCV screening, and testing and counseling; (3) risk reduction within injecting relationships; (4) injection cessation and "breaks"; (5) scaled-up needle/syringe distribution, HCV treatment, and vaccines, according to suggestions from mathematical models; and (6) "combination prevention." With ongoing and expanding transmission of HCV, there is little doubt that there is a need for implementing what is in the prevention "toolbox" as well as adding to it. Strong advocacy and resources are needed to overcome challenges to providing the multiple and comprehensive programs that could reduce HCV transmission and associated burden of disease worldwide in people who inject drugs

AB - The hepatitis C virus (HCV) virus epidemic is ongoing in the United States and globally. Incidence rates remain high, especially in young adult injection drug users. New outbreaks of HCV in the United States among young adults, in predominantly suburban and rural areas, have emerged and may be fueling an increase in HCV. This paper discusses some key HCV prevention strategies that to date have not been widely researched or implemented, and wherein future HCV prevention efforts may be focused: (1) reducing sharing of drug preparation equipment; (2) HCV screening, and testing and counseling; (3) risk reduction within injecting relationships; (4) injection cessation and "breaks"; (5) scaled-up needle/syringe distribution, HCV treatment, and vaccines, according to suggestions from mathematical models; and (6) "combination prevention." With ongoing and expanding transmission of HCV, there is little doubt that there is a need for implementing what is in the prevention "toolbox" as well as adding to it. Strong advocacy and resources are needed to overcome challenges to providing the multiple and comprehensive programs that could reduce HCV transmission and associated burden of disease worldwide in people who inject drugs

U2 - 10.1093/cid/cit300

DO - 10.1093/cid/cit300

M3 - Article

C2 - 23884063

VL - 57

SP - S32-S38

JO - Clinical infectious diseases

JF - Clinical infectious diseases

SN - 1058-4838

IS - Suppl. 2

ER -

ID: 2186181